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Abstract
A hallmark of tumor cell survival is the maintenance of elongated telomeres. It is known that antiviral reverse tran-
scriptase inhibitors (RTIs) such as azidothymidine (AZT) and didanosine (ddI) lead to telomere shortening at high,
potentially toxic concentrations.We hypothesized that those drugsmight have synergistic effects enabling successful
therapy with low, nontoxic concentrations. Biologic effects of AZT and ddI were analyzed at concentrations that cor-
respond to minimal plasma levels achieved during human immunodeficiency virus therapy. Long-term coapplication
of low-dose AZT and ddI induced a significant shortening of telomeres in the tumor cell lines HCT-116, SkMel-28,
MelJuso, and Jurkat. Treatment of cells with both RTI, but not with single RTI, led to a significant accumulation of
γH2AX, to p53 phosphorylation, and to cell apoptosis in all cell lines. Oral low-dose dual RTI application but not low-
dose single RTI application was associated with a significantly reduced tumor growth of HCT-116 cells in mice. This
antiproliferative activity of the combined use of AZT and ddI at low, clinically applicable concentrations warrants
clinical testing in human solid cancer.
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Introduction
Telomeres at the end of linear chromosomes contain tandem arrays
of the GT-rich nucleotide sequence 5′-TTAGGG-3′ [1]. In normal
somatic cells, telomeres generally shorten with every cell division [2].
Physiological erosion of telomeres induces cell senescence until crit-
ically shortened telomeres result in natural cell death [3,4]. On a mo-
lecular level, telomere shortening is associated with binding and
phosphorylation of DNA damage recognition proteins such as the
histone H2AX [5]. Cancer cells develop mechanisms that inhibit
the physiological shortening of telomeres leading to the unlimited
capacity to proliferate that inhibits not only cancer cell death but also
cancer cell senescence. Thus, drugs leading to telomere shortening
should allow selective purging of tumor cells [6–9].
Most approaches targeting telomeres in cancer cells have focused on
the inhibition of telomerase [6], a ribonucleoenzyme promoting telo-
mere elongation. Because telomerase is a reverse transcriptase, research
initially focused on known nucleoside reverse transcriptase inhibitors
(RTIs) such as azidothymidine (AZT) [6]. High concentrations of
RTIs effectively inhibited telomerase activity [7–9]. The advantage of
these drugs was their established pharmacodynamic and toxicity profile
because RTIs were used for a long time as a cornerstone in human
immunodeficiency virus (HIV) therapy. It was therefore reasonable
to initially assess AZT in HIV-associated lymphomas [10]. Today,
AZT is established as first-line therapy in human T-cell lymphatic virus
type I–associated adult T-cell leukemia/lymphoma [11,12].
This prompted the investigation of the antiproliferative effect of
AZT in other tumor entities. It had been established that short-term
(2-3 days) AZT treatment induced telomere shortening [13–15] and
cell cycle arrest [16] at high concentrations (>100 μM) [9,14,15].
Long-term treatment required the reduction of the biologically effec-
tive dose to concentrations below 100 μM [17,18]. However, animal
data revealed only marginal effects of low-dose AZT monotherapy in
solid cancers [19].
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In HIV therapy, RTIs are usually given as a combination therapy.
We have therefore hypothesized that synergistic effects of RTIs might
also enhance their antiproliferative activity in a cancer setting. We
reasoned that synergism might allow for a reduction in the required
effective therapeutic dose of the drugs to concentrations that are well
tolerated in humans. In support of our hypothesis, we found that pro-
longed treatment of different types of cancer cells with AZT in combina-
tion with didanosine (ddI) induced telomere attrition at concentrations
applicable to humans. The RTI combination also significantly increased
apoptosis in vitro and led to distinct therapeutic benefits in vivo.
Materials and Methods
Cell Cultures
Human colorectal carcinoma cells HCT-116, SkMel-28, and
Jurkat cell lines were purchased from ATCC (Wesel, Germany).
Melanoma cell line MelJuso was a gift from J. Lehman from the In-
stitute of Immunology, University of Munich. HCT-116 and mela-
noma cell lines SkMel-28 and MelJuso were maintained in Dulbecco
modified Eagle medium/F12 (GibcoLife Technologies, Grand Island,
NY). Acute T-cell leukemia (Jurkat) cells were maintained in RPMI-
1640 (GibcoLife). Media were supplemented with 10% fetal bovine
serum (GibcoLife) and 1 mM L-glutamine (Sigma-Aldrich, Vienna,
Austria). Cells were maintained at 37°C/5% CO2 and propagated
twice weekly with 0.5% trypsin (GibcoLife). 3′-Azido-3′-deoxythymidine
(AZT) and 2′,3′-dideoxyinosin (ddI) (Sigma-Aldrich) were dissolved
in Dulbecco modified Eagle medium, and the inhibitor-containing
medium was changed every 48 hours. Cells were harvested every 72 to
96 hours, counted in a Burker chamber (two counting sessions per
sample), and replated at the same density.
Telomere Length Determination by Southern Blot
Genomic DNA was extracted from 1 × 107 cultured tumor cells
using Maxwell 16 Cell and Tissue DNA Purification Kit (Promega,
Madison, WI). Mean telomere length was measured using the Telo-
TAGGG telomere length assay (Roche Diagnostics GmbH, Mannheim,
Germany). Briefly, 1 μg of genomic DNAwas digested withHinfI/RsaI
mixture (5 U per restriction enzyme) and separated on 1% agarose gels.
Fractionated DNA fragments were transferred onto nylon membrane
(Roche Diagnostics GmbH) and hybridized with a digoxygenin-labeled
telomere oligo-probe (TTAGGG)3. The hybridized probe was incu-
bated with a digoxygenin-specific antibody covalently coupled to alka-
line phosphatase. The immobilized telomere probe was visualized by a
highly sensitive chemiluminescent substrate for alkaline phosphatase,
and telomere DNA detection was finally achieved by the ChemiSmart
2000 chemiluminescence imaging system (Vilber Lourmat, Eberhardzell,
Germany). The signal intensity was evaluated by densitometric analysis
with ImageQuant software 5.0, Molecular Dynamics, Sunnyvale, CA,
and the telomeric repeat fragments (TRFs), an indicator for mean telo-
mere length of a sample, were calculated according to ∑(ODi)/∑(ODi/
Li), where OD is the signal intensity and L is the length (kb) at the gel
point i. Li represents the mean molecular size of 40 equal intervals of
the telomeric smears in the range of 0.5 to 23 kb.
Real-time Polymerase Chain Assay
Mean telomere length was further measured from total genomic
DNA by using a real-time quantitative polymerase chain reaction
(PCR) method previously described [20]. The premise of this assay is
to measure an average telomere length ratio by quantifying telomeric
DNA with specifically designed primer sequences and normalizing to
the quantity of a single-copy gene.
Briefly, the telomere repeat copy number to single gene copy num-
ber (T/S) ratio was determined using an Applied Biosystems (Foster
City, CA) 7500 ThermoCycler in a 96-well format. Twenty nanograms
of genomic DNA or water as nontemplate control was distributed in a
96-well plate. The same volume of 2× Power SYBR Green MasterMix
(Applied Biosystems, Life Technologies, Inchinnan, Scotland) was
added with 400 nM each of forward and reverse primers to amplify
the telomere repeats (T) or the 36B4 single-copy gene (S) in single-plex
PCR assays. The telomere assay consisted of Tel-1 primer (CGGTTT-
GTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT) and of
Tel-2 primer (GGCTTGCCTTACCCTTACCCTTACCCT-
TACCCTTACCCT). The 36B4 assay consisted of the 36B4u primer
(CAGCAAGTGGGAAGGTGTAATCC) and the 36B4d primer
(CCCATTCTATCATCAACGGGTACAA). The 36B4 gene, which
encodes acidic ribosomal phosphoprotein PO, is located in chromo-
some 12 [21].
The reaction proceeded for 1 cycle at 95°C for 10 minutes followed
by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute. All
samples of telomere reactions were determined in triplicate, whereas
single-copy gene (36B4 ) reactions were performed in duplicates, and
the SD threshold for both reactions was set to 0.5. Results exceeding
this deviation limit were excluded and repeated. The collected data of
telomere repeats were evaluated by the ΔΔC t method [22], normal-
ized to the single-copy gene 36B4 and set in relation to the untreated
cells for reference resulting in relative quantity values for telomere
DNA repeat content. PCR products of T and S reactions were vali-
dated by gel electrophoresis (data not shown).
Fluorescence In Situ Hybridization Analysis
For quantitative fluorescence in situ hybridization of interphase
nuclei (Q-FISH), 1 × 106 cancer cells were seeded at a low density
and cultured in growth medium with 10% fetal calf serum (FCS) for
48 hours. Colcemid (10 ng/ml) was given for 120 minutes, and nuclei
were prepared according to standard methods. Telomere length based
on telomere signals of individual chromosomes was detected using the
Telomere PNA FISH kit/FITC (Dako Denmark A/S, Glostrup,
Denmark) by essentially following the reported protocol [23]. Inter-
phase nuclei were captured by confocal microscopy (63× 1.4 oil magni-
fication) and were quantitatively evaluated with Telomere Measurement
Software (obtained from British Columbia Cancer Research Centre).
Immunofluorescence Staining
Adherent cells were cultured on four-chamber coverslips (NUNC,
lab-tek chamber slide with cover; Dako) for 48 hours to minimize
stress that may arise during passage. Nonadherent cells ( Jurkat) were
seeded on coverslips by using a cytospin device. Cell density was 1 ×
105 per slide. After preparing slides, all cells were washed and fixed in
4% formaldehyde for 10 minutes at 37°C. The coverslips were sub-
sequently washed three times with PBS, and nonspecific binding sites
were blocked in blocking solution (PBS containing 10% FCS, 0.3%
Triton X-100, and 3% bovine serum albumin) for 30 minutes. Cells
were then incubated with purified mouse anti–human p53 (Ser-15)
(1:400 dilution 554294; BD Biosciences, Erembodegem, Belgium)
or rabbit anti-γH2AX (Ser-139) (1:1000 dilution; Bethyl A300-031,
Bethyl Laboratories, Inc, Montgomery, TX) in blocking solution for
60 minutes. Subsequently, cells were washed three times with PBS
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and incubated with goat anti-rabbit Alexa Fluor 568 (1:1000 dilution;
Molecular Probes, Life Technologies, Inchinnan, Scotland) or rabbit
antimouse Alexa Fluor 488 (1:1000 dilution; Molecular Probes) in
blocking solution for 60 minutes at 37°C. The nuclei were stained with
Draq5 (1:750 dilution; Sigma), washed with PBS, and mounted in a
mounting medium for fluorescence (Vectashield; VectorLabs, Burlin-
game, CA). Images were captured with a confocal microscope at 40×
1.3 oil or 63× 1.4 oil magnification.
Figure 1. Effect of combined AZT/ddI treatment on telomere length in tumor cell lines as assessed by Q-FISH analysis of interphase
nuclei. Treatment was applied for 4 weeks. (A) Representative FISH microscopy images of interphase nuclei stained for telomeres with
FITC-labeled PNA oligonucleotides (green pixels; magnification, ×40). (B) Relative telomere length values as determined by Q-FISH in
relation to the untreated control cells set to 100%. Columns represent mean values of at least two independent experiments; the error
bar indicates the standard deviation. *P ≤ .05.
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Cell Cycle and Cell Death Analysis Using Annexin V/
Propidium Iodide Double Staining Assay
After treatment, 106 cancer cells were harvested, washed twice
with PBS, and resuspended in 500 μl of PBS. Then cells were slowly
immersed in 5 ml of 70% ethanol and frozen at −20°C for 2 hours.
Cells were then stained with 200 μl of propidium iodide (PI; Sigma)
dissolved in 10 ml of PBS and 2 mg of DNase-free RNase (Sigma)
and 0.1% Triton-X for 15 minutes. Subsequently, cells were measured
by FC500 flow cytometer (Becton Dickinson, Franklin Lakes, NJ). For
annexin V staining, the harvested cells were adjusted to a concentration
of 1 × 106/ml. One hundred microliters was stained with 5 μl of
PI solution and 5 μl of FITC-conjugated annexin V (BD Pharmingen,
Erembodegem, Belgium). Measurements were performed by flow
cytometer and followed the protocol and the calculations of Multi-
Cycle AV for Windows, Version 6.0 (Phoenix Flow Systems, Inc,
San Diego, CA).
Figure 2. Effect of combined AZT/ddI treatment on telomere length in tumor cell lines as determined by real-time PCR and Southern blot
analysis. (A) Telomeric length as assessed by real-time PCR analysis in different tumor cell lines after 4 weeks of treatment. The y axis of
box plots indicates the relative quantity (RQ). RQs are normalized to a single-copy gene (36B4) and a reference sample and are log-
transformed (see Materials and Methods). The box plot summarizes the mean, maximum, and minimum; error bars indicate the
SEM from at least two independent experiments performed in triplicates. *P ≤ .05. **P ≤ .001. (B) Telomeric length as assessed by
Southern blot hybridization in HCT-116 cells after 4 weeks of treatment. The DNA molecular weight (kb) of a standard sample is given on
the left. The calculated mean TRF is indicated by a bar in each sample lane, and the calculated values are given below.
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Tumor Xenografts and Treatment of Animals
Athymic nude mice (5 weeks old; Charles River, Sulzfeld, Ger-
many), kept in accordance with the European Union guidelines,
were inoculated subcutaneously with 2 × 106 HCT-116 colon carci-
noma cells in 100 μl of PBS. AZT and ddI were dissolved in ddH2O
and added to the drinking water. Animals received AZT at a concen-
tration of 10 mg/kg and ddI at 20 mg/kg, respectively, with daily
changes of the drinking water. Mice were randomized to treatment
groups at the day of tumor inoculation. Treatment started 14 days
after tumor implantation when tumor size was ∼35 mm3. The total
number of animals in each treatment group was 8. Tumor growth was
monitored every third day by caliper measurements; volumes were
calculated using the formula: length × length × width × 0.52 [24].
After reaching a tumor volume of 600 mm3, the mice were killed.
Tumors were excised and fixed in formaldehyde.
Immunohistochemistry
To detect the Ki-67 antigen in formalin-fixed/paraffin-embedded
tissue sections, slides were deparaffinized in xylene and rehydrated in
graded ethanol. Ten-micrometer-thick sections were immersed in a
trypsin buffer solution (0.05% trypsin, 1mMCaCl2, PBS) for 15minutes
at 37°C. Slides were incubated with an anti–Ki-67 antibody (1:250
dilution; Abcam, Cambridge, UK). The nonspecific staining was blocked
by incubation for 30 minutes with 10% FCS. The sections were incu-
bated with Alexa Fluor 568 as a secondary antibody (1:1000 dilution;
Molecular Probes). Nuclei staining positive for Ki-67 were defined by
visual determination in three or more randomly selected fields per cross
section at 40× magnification. Cross sections were done at the biggest
diameter of the tumor. Ki-67 “positive” staining was defined as at least
three positive areas per cross section.
Microscopy
Deconvolution microscopy was carried out using a Zeiss Axioplan
2 microscope, with LSM 510 Meta microscopy laser system, and a
ZEN 2008 restoration microscopy system (Zeiss, Inc, Jena, Germany).
In each case, five independent fields were captured, and representative
images were selected. All images were digitally processed for presenta-
tion with Adobe Photoshop CS4.
Statistical Analysis
All data are represented by the mean and SEM of least two or three
independent experiments. Statistical analysis was performed using the
statistical software SPSS Statistics 17.0.0 (SPSS Software, Armonk, NY)
and with GraphPad Prism Version 5 (GraphPad Software, La Jolla,
CA). P < .05 was considered statistically significant.
Results
Effect of AZT and ddI Double Treatment on Telomere Length
First, we investigated a possible additive effect of AZT and ddI with
respect to telomere shortening. We used AZT at a concentration of
0.4 μM and ddI at a concentration of 6.0 μM. Those concentrations
correspond to the lowest serum concentrations measured in HIV
patients treated orally with those drugs.
We treated the following tumor cell lines with AZT and ddI for
32 days: the colorectal carcinoma cell line HCT-116, the T-lymphocyte
cell line Jurkat and two human skin melanoma cell lines, MelJuso and
SkMel-28. The size of telomeres was first assessed by Q-FISH analysis of
interphase nuclei. The combined treatment of cells with AZT and ddI
induced a substantial and significant decline of telomere length in all four
Figure 3. Effect of combined AZT/ddI treatment on apoptosis in tumor cell lines. Treatment was carried out for 3 weeks. Apoptosis was
determined by annexin V/PI double staining and flow cytometry. *P ≤ .05.
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Figure 4. Effect of combined AZT/ddI treatment on the nuclear accumulation of γH2AX and phosphorylated p53 in tumor cell lines.
Tumor cells were treated for 4 weeks: AZT, 0.4 μM azidothymidine; ddI, 6.0 μM didanosine; double, 0.4 μM AZT and 6.0 μM ddI. (A)
Representative immunofluorescence images of γH2AX (Alexa Fluor 568, red) and stained nuclei (Draq5, blue) (magnification, ×60) of
Jurkat cells. Treatment of cells as indicated (a) control, (b) AZT, (c) ddI, and (d) double. (B) For quantitative information, the percentage
of positive cells is indicated by graphs. Results represent the mean of two independent experiments. Error bar, SD. (C) Representative
images of fluorescence microscopy of p53 staining (FITC, green) and DNA counterstaining (Draq5, blue) for Jurkat cells (magnification,
×60) and MelJuso and HCT-116 cells (magnification, ×40). Treatment as indicated (a) control, (b) AZT, (c) ddI, and (d) double. *P ≤ .05.
**P ≤ .001.
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cell lines (Figure 1, A and B). As expected, there was no major change of
telomeric length in the presence of AZT alone.
We further verified the observed effect of RTI on the length of
telomeres by real-time PCR (Figure 2A). Corresponding to the data
obtained by Q-FISH analysis, real-time PCR results revealed that dou-
ble RTI treatment induced a significant shortening of telomeres in all
four cell lines analyzed. Single-agent treatment with ddI only induced
significant telomere shortening in MelJuso and Jurkat cells.
To further illustrate the reduction of telomeric DNA during RTI
treatment, we determined the TRFs by Southern blot analysis in one
of the cell lines (Figure 2B). We used the HCT-116 cell line in this
experiment because we have also chosen this cell line for in vivo experi-
ments. The calculated mean TRF in the untreated control was 2.8 kb.
Double treatment induced a slow shortening to 2.0, 1.68, and 1.66 kb
after 11, 19, and 32 days, respectively. This attrition became significant
at day 19. Single treatment with ddI was associated with a moderate
and nonsignificant shortening of mean telomere length. AZT treatment
did not affect the length of telomeres in this assay.
Combined Treatment of Cells with AZT and
ddI Increases Apoptosis
Telomere shortening can promote cell death [2–4]. We therefore
determined the level of apoptosis in treated and untreated tumor cell
lines by annexin V staining (Figure 3). The double RTI treatment
induced substantially higher levels of apoptosis in all four cancer cell
lines compared with untreated cells. In contrast, single-agent treat-
ment did not lead to significantly higher levels of annexin V–positive
cells. Lowering the concentrations of RTI (to 0.04 μM AZT and
0.6 μM ddI) in double treatment abrogated induction of apoptosis
(data not shown).
Combined Treatment of Cells with AZT and ddI Enhances
the Number of γH2AX Foci and the Phosphorylation of p53
We next analyzed the effect of RTI treatment on the phosphory-
lation of histone H2AX (Figure 4, A and B). The phosphorylated
γH2AX serves as a marker for DNA damage, senescence, and cell
death. It is known that tumor cells have higher spontaneous phos-
phorylation of H2AX, when compared to nonmalignant cells. In ac-
cordance with the literature [25], γH2AX-specific signals were found
in 8.3%, 13.4%, 16.3%, and 16.2% of the nuclei in untreated HCT-
116, Jurkat, MelJuso, and SkMel-28 cells (mean values). Double
treatment of tumor cell lines for 4 weeks induced a significant rise of
γH2AX-positive signals to 41.4%, 54.0%, 41.9%, and 57.3%, respec-
tively. In contrast, single-drug treatment never led to a significant
increase in γH2AX-specific signals.
Figure 5. Effect of combined AZT/ddI treatment on cell cycle and proliferation of HCT-116 cells. Cells were exposed to RTI up to 22 days.
(A) Effect of combined AZT/ddI treatment on cell cycle progression as determined by PI staining. The percentage of cells in distinct cycle
phases is specified. The experiment was repeated once with similar results. (B) Effect of AZT/ddI treatment on cell proliferation and
death. Columns represent the mean of triplicate cell counts ± SD. The cell number is expressed in percent to control cultures receiving
no treatment. Empty bar indicates untreated control; dark gray bar, AZT; light gray bar, ddI; black bar, double treatment. *P ≤ .05.
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Previously, it has been shown that γH2AX is associated with activa-
tion (phosphorylation) of p53 [5]. We therefore determined serine-15
phosphorylation of p53 in response to RTI therapy by immunocyto-
chemistry. A functional p53 pathway has been reported for HCT-116,
MelJuso, and Jurkat cells. Thus, we focused on these three cell lines for
analysis. RTI treatment induced a strong (>70% positive cells) signal
specific for serine-15 phosphorylation of p53 in all three cell lines,
whereas the effect of single agents was comparably modest (Figure 4C).
Effect of RTIs on Cell Cycle and Cell Growth of
HCT-116 Cells
DNA damage, telomere length attrition, and induction of γH2AX
usually lead to cell cycle arrest. We determined the effect of RTI on the
cell cycle status of HCT-116 cells. Double and single RTI treatment
led to an accumulation of cells in the S phase and a corresponding de-
crease in the G0/G1 peak: a representative picture is shown in Figure 5A
(flow cytometry histogram of HCT-116 cells). We next determined the
effect of RTI therapy on cell proliferation and survival by establishing
the cell count. Double low-dose RTI therapy significantly reduced
the cell number by approximately 40% after 16 to 22 days of treat-
ment, whereas single agents had no substantial effect on cell count
(Figure 5B).
RTIs Reduce the Growth of Human Tumor Xenografts
in Athymic Nude Mice
We then investigated whether low concentrations of AZT in com-
bination with ddI would affect tumor growth in vivo. HCT-116 cells
were injected in the right flank of nude mice. Treatment of animals
with AZT and/or ddI was started when the tumors were grown to a
volume of 35 mm3. The drug concentration applied in drinking water
to the mice corresponded to the therapeutic dose recommended for
HIV patients. Tumor growth was significantly reduced in animals
treated with both drugs compared to untreated mice (Figure 6A).
After 29 days, the mean tumor volume was 163 ± 84 mm3 in the
combined treatment group compared with a mean volume of 593 ±
99 mm3 in the control group (P ≤ .05). In contrast, single treatment
was not associated with significant therapeutic effects. The cor-
responding Kaplan-Meier graph illustrates the increased survival of
animals treated with the RTI combination (Figure 6B).
To further investigate the effect of RTI treatment on the growth of
tumor tissue in vivo, tumor samples of killed mice were analyzed for
the cellular proliferation marker Ki-67 (Figure 6C ) as detected by
immunohistochemical staining. In untreated animals, each tumor
showed more than five Ki-67–positive spots per cross section. In
single agent–treated mice, each tumor revealed at least three Ki-67–
positive spots per slide. In contrast, histologic slides of xenografts
derived from mice receiving double RTI treatment only revealed a
single positive spot in two of eight samples. Thus, the staining pattern
of Ki-67 correlated with the rate of tumor growth.
Discussion
This is the first demonstration that the combined use of low-dose
AZT and ddI reduces tumor cell growth in vivo. Most importantly,
anticancer effects were observed at drug concentrations applied dur-
ing oral treatment of HIV patients. Thus, an important aspect of our
preclinical finding is the fact that drug dosing acceptable to human
patients was effective.
With regard to the molecular mechanism, we could demonstrate
that low-dose dual RTI treatment leads to a significant shortening of
telomeres and induces a DNA damage response and apoptosis of
tumor cells. In line with previous observations [26,27], we propose
that it is essential to apply RTIs for several weeks to achieve biologic
effects at low drug concentrations. Furthermore, our assays clearly
demonstrated that cotreatment with AZT and ddI, but not single
treatment, was able to induce telomere shortening in all tested human
Figure 6. Therapeutic effect of combined AZT/ddI treatment on
HCT-116 derived tumors in nude mice. Treatment was started
when tumors reached the size of ∼35 mm3. Groups (n = 8) are
indicated as follows: –♦– Bidest.water; –▪– 10 mg/kg per day AZT;
–▴– 20 mg/kg per day ddI; –x– combination of AZT and ddI. (A) Meanvalues of tumor volumes of different groups are given. Error bars,
SD. *P ≤ .05. (B) Kaplan-Meier plot illustrating survival of the dif-
ferent groups. (C) Immunohistochemical staining of the proliferation
marker Ki-67 in excised murine tumors. A representative picture
(magnification, ×40) for each group is shown. Treatment of mice
as indicated on the top: (a) control, (b) AZT, (c) ddI, and (d) double.
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cancer cell lines. This indicates that the combination of these drugs
may be widely applicable to various tumor entities.
It is well known that RTIs efficiently inhibit telomerase activity
when applied at high concentrations. However, studies conducted by
others [6,7,13] and us (TRAP assay; data not shown) indicate that, at
low levels, RTIs do not interact with the known telomere maintenance
proteins such as telomerase, indicating another mechanism of action.
Alternative mechanisms of action can be envisioned by an inhibition of
other cellular reverse transcriptases such as encoded in LINE-1 elements
or human endogenous retroviral sequences. This notion is also sup-
ported by the facts that 1) LINE-1 and human endogenous retroviral
elements are known to be activated in cancer cells and 2) the finding that
AZT and ddI combination treatment does not lead to telomere attrition
in nonmalignant cells. Ongoing experiments are performed to elucidate
the interaction of RTI with those tumor-associated reverse transcriptases.
We have demonstrated an accumulation of γH2AX during the
dual RTI treatment. H2AX is activated through double-strand breaks
and cell stress. Thus, H2AX activation can occur as a consequence of
telomere attrition, but it can also accumulate by telomere-unrelated
mechanisms. On the basis of the present data, we cannot conclusively
determine the mechanism of γH2AX activation in our setting:
Telomere-independent mechanisms can be envisioned because AZT
is incorporated into the DNA. Alternatively, ddI may enhance H2AX
incorporation [16]. However, a telomere-dependent activation of
H2AX is supported by the fact that H2AX was not detected before
4 weeks of treatment (data not shown). Four weeks seem to be nec-
essary for progressive degradation of telomere ends and for triggering
the DNA damage signal by uncapped telomeres. Direct damage of
DNA by the drugs would be expected to occur more rapidly. Irrespec-
tive of the mechanism of activation, we conclude that the activation of
H2AX by dual RTI treatment but not by single-agent therapy greatly
supports this drug combination as an anticancer regimen.
Activation of H2AX can lead to cell death, which has been de-
scribed to be mediated by serine-15 phosphorylation of p53 [5].
Along this line, we could demonstrate a concurrent phosphorylation
of γH2AX and increased p53 phosphorylation in HCT-116, MelJuso,
and Jurkat cells. However, RTI treatment also induced cell death in
SkMel-28, which lacks a functional p53 pathway. Thus, RTI-induced
cell death is not necessarily linked to a functional p53 pathway. This
correlates with the fact that p53-independent γH2AX-mediated cell
death has been described in other studies [25].
With respect to cell cycle arrest, we could observe a shift from the
G0/G1 phase to the S phase in HCT-116 cells by double treatment.
In line with previous publications, single RTI treatment also induced
comparable changes [28]. This observation suggests that effects of
RTI on cell cycle might be uncoupled to—and do not explain—drug
effects on telomere lengthening, apoptosis, and growth inhibition
in vitro. It should be noted that there is also only limited amount
of consistent data of RTI effects on cell cycle progression in the litera-
ture supporting a loose interaction.
Lately, a number of clinical trials have been initiated with new
telomere-interacting agents and telomerase inhibitors as well as with
antitelomerase vaccines [29]. These agents have been developed owing
to the apparent therapeutic potential resulting from the pathologic telo-
mere regulation in cancer cells. They include drug candidates inhibiting
telomerase by nonnucleoside small molecules such as BiBR1532 [30]
or oligonucleotide inhibitors of telomerase activity such as GRN163L
[26,27,31], the latter being applied in phase 2 trials for breast cancer,
lung cancer, and myeloma. A major concern of the clinical application
of AZT as a telomerase inhibitor is its toxic side effects on healthy tissue
observed at high drug concentrations. Specifically, it was shown that
RTI can enhance mutagenesis in vitro and can lead to transplacental
genotoxicity [32]. The herein used therapeutic concentrations of the
AZT/ddI combination had no effect on telomeres in human fibroblasts
(T.A. and M.B., unpublished observations) indicating a differential
susceptibility of malignant and nonmalignant cells to these drugs at
low concentrations. Similarly, a differential reactivity toward malignant
versus nonmalignant tissue has been described for other telomerase
interactive agents [32,33]. In conclusion, the successful use of the com-
bination of two known RTI such as AZT and ddI at low concentrations
in a murine cancer model might reintroduce these drugs in the onco-
logical therapy for solid cancers. The important aspect of using the
drugs in combination mirrors their application and effectiveness in
HIV therapy.
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